The Class I HDAC Inhibitor Valproic Acid Strongly Potentiates Gemcitabine Efficacy in Pancreatic Cancer by Immune System Activation.
Amber BlaauboerPeter M van KoetsveldDana A M MustafaJasper DumasFadime DoganSuzanne van ZwienenCasper H J van EijckLeo J HoflandPublished in: Biomedicines (2022)
These results provide a strong rationale for combining gemcitabine with VPA treatment. For the first time, we present intratumor changes and show activation of the immune system. Clinical trials are warranted to assess efficacy and safety of this novel combination in pancreatic cancer patients.